Page 3 - Dr Lal Pathlabs

Diagnostic players ride on changes in health insurance to beat slowdown

Metropolis, Dr Lal and Thyrocare are likely to see more gains led by expansion, increasing penetration, preventive testing and government's Ayushman Bharat scheme

Volume growth key to Dr Lal Pathlab's health; stock rises over 4%

Firm banking on acquisitions, and rationalisation of prices

Dr Lal PathLabs to buy 70% stake in a new firm to strengthen presence in MP

Dr Lal PathLabs' board has approved the signing a binding term sheet for the acquisition

Dr Lal PathLabs reports 12.8% jump in net profit at Rs 574 million

Operating margin declined to 28.5 per cent as against 29 per cent a year ago

Dr. Lal PathLabs surges 16% on strong Q4 results

The stock surged 16% to Rs 931, also its 52-week high on the BSE in intra-day trade after the company reported a better than expected 27% YoY growth in net profit at Rs 402 million in Q4FY18.

Q1 results: Dr Lal PathLabs' health improves

Better margins and focus on cost rationalisation to drive earnings

Dr Lal PathLabs: Street worried over rising pressures

The stock of Dr Lal Pathlabs fell 6.4 per cent after brokerages cut their margins and earnings estimates sharply for the company due to rising pressures on pricing and volumes. Morgan Stanley, which has cut its target price to Rs 700 from Rs 888, believes that the company will face substantial pressure on both pricing and volumes given competitive intensity. Some of the pressures were visible in the March quarter performance, which saw the company's operating profit margins decline 298 basis points year-on-year to 23.6 per cent.Competition in the business-to-business (B2B) segment, promotional and employee expenses as well as costs associated with setting up new labs, added to the pressure. The B2B segment, which includes revenues from nursing homes and hospitals among others, accounts for 40 per cent of the company's revenues. Going ahead, analysts at Nomura believe that the company's operating profit margins could be under pressure and could contract 100 to 200 basis points given ...

Dr Lal PathLabs hits 52-week low after block deals

The stock slipped 6.5% to Rs 780 after two per cent of total equity changed hands on NSE and BSE.

Dr Lal PathLabs eyes growth via acquisitions

Dr Lal PathLabs is focusing on 'inorganic growth'

Dr Lal Pathlabs' strong brand and network keep it in the pink of health

Dr Lal Pathlabs is Business Standard Star SME of the Year 2016

Gradual sales recovery for Dr Lal PathLabs

December quarter could come under pressure, but growth set to improve from March quarter

Dr. Lal PathLabs hits new high; zooms 100% from issue price

The stock hit a new high of Rs 1,114, rallied 21% in past two trading sessions from Rs 922 on the BSE.

Dr Lal PathLabs faces pricing pressure, margin erosion

In its annual report, the company raised concerns of pricing control at the time of epidemics

Dr Lal PathLabs eyeing 18% growth in FY17

The company had posted a revenue of Rs 791.3 crore for the fiscal year 2015-16

Dr Lal PathLabs Q4 profit up 20% at Rs 34 cr

Total income from operations up 15% Rs 198 cr for the quarter; full-year profit up 38% at Rs 132 cr

Dr. Lal PathLabs hits highest level since listing

The stock has soared 11% to Rs 947, its highest level since listing on the bourses in December last year